Fund Allocation - The net proceeds from the subscription amount to approximately HKD 19,400,000, with 60% allocated for expanding existing longevity science and new biopharmaceutical product trading businesses [4] - 11,640 thousand HKD (60%) of the net proceeds has been fully utilized for business expansion, while 7,760 thousand HKD (40%) has been allocated to general working capital [5] Stock Options and Incentives - No stock options were granted under the 2022 stock option plan during the fiscal year 2024 [6] - The total number of shares available for grant under the stock incentive plan and the 2022 stock option plan is 38,701,026 shares as of January 1, 2024, and December 31, 2024 [8] - The company clarified that the number of shares that could be issued for stock options and incentives during the fiscal year 2024 is zero, contrary to the previously reported 16.02% [9]
中基长寿科学(00767) - 2025 - 年度业绩